Skip to main content
15/07/2022

Vall d'Hebron organizes the first international congress on the ERK5 protein in cancer

Congrés ERK

15/07/2022

The meeting allows establishing the basis for collaboration between experts from around the world, with the aim of promoting research on this protein and its role in cancer.

On July 14 and 15, Vall d'Hebron hosted the first international meeting on ERK5 signaling, a protein whose role in tumor development has been under special investigation in recent years. This congress has been promoted by Dr. José M. Lizcano, head of the Protein Kinases and Cancer group, and Dr. Miquel Segura, principal investigator of the Childhood Cancer and Blood Disorders group, both from Vall d'Hebron Research Institute (VHIR) in order to bring together most of the experts working on this protein worldwide.

ERK5 protein is a kinase that plays an important role in the control of tumor cell survival and proliferation. Therefore, ERK5 has recently been proposed as a possible therapeutic target for the treatment of different types of adult tumors, such as endometrial, lung, colon, breast, liver and prostate tumors, and also in pediatric solid tumors such as neuroblastoma. Recent studies also indicate that ERK5 may be involved in resistance to targeted cancer therapies.

The congress held this week presented the latest developments in ERK5 and included discussions on the future of research in this field. "This first meeting allows us to establish the basis for collaboration to promote studies of this factor with the aim of being able to take the advances to clinical practice", says Dr. Miquel Segura. "The research we are carrying out will allow us to promote ERK5 as a prognostic marker of the disease and also as a therapeutic target", adds Dr. José M. Lizcano.

Nearly 40 specialists in this field of research attended the conference, both from Spanish centers and from the United States, Italy, Germany, the United Kingdom and France.

Related news

Inhibition of the ERK5 protein kinase reduces the proliferation and survival of endometrial cancer cells, and potentiates standard chemotherapy.

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

Vall d’Hebron and UAB researchers studied the antitumoral action of protein kinase ERK5 inhibitor drugs, and found out they accelerate toxic autophagy.

Related professionals

Miguel Segura Ginard

Miguel Segura Ginard

Senior researcher
Childhood Cancer and Blood Disorders
Read more
Jose Miguel Lizcano De Vega

Jose Miguel Lizcano De Vega

Head of group
Protein kinases in cancer research
Read more
Elisabet Megías Roda

Elisabet Megías Roda

Administration and Management
Protein kinases in cancer research
Read more
Sergio Espinosa Gil

Sergio Espinosa Gil

Predoctoral researcher
Protein kinases in cancer research
Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.